MedTrace Logo

Observational Trial on Cytokine Adsorption in Sepsis

NCT04306419 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-11-04

No results posted yet for this study

Summary

To determine the specific population of critically ill septic patients who benefit most from cytokine adsorption therapy with the HA-380 cartridge. Benefit of the treatment will be assessed on the basis of:

* The scope of the effect of cytokine adsorption therapy in this specific population of critically ill patients expressed by cytokine variability within the patients
* The scope of cytokine changes in passing the adsorption cartridge my measuring cytokine levels in the patient's blood directly before passing through the cartridge and directly after having passed through the cartridge.
* The scope of changes in organ dysfunction expressed by SOFA scores that are repeatedly calculated during the treatment with cytokine adsorption and then daily until day 7 of the ICU treatment.
* The scope of changes on cellular function on immune cells in serum samples taken before and after cytokine adsorption therapy.
* The scope of removal of anti-infective drugs from the blood in passing through the cytokine adsorption cartridge by measuring antibiotic drug levels in the patients blood during the cytokine adsorption therapy
* 30 day and 90 day mortality and location status in survivors

Conditions

  • Sepsis
  • Septic Shock
  • Multiple Organ Failure

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2023-06-28
Completion
2024-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04306419 on ClinicalTrials.gov